Compare D R Horton Inc (DHI) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? D R Horton Inc trades at $146.36 (market cap $42.18B), while Ginkgo Bioworks Holdings Inc trades at $7.42 (market cap $505.73M). The key difference: D R Horton Inc is far larger — about 83.4× Ginkgo Bioworks Holdings Inc's market cap, and D R Horton Inc pays a 1.19% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DHI | DNA | |
|---|---|---|
Market Cap | $42.18B | $505.73M |
Sector | Consumer Cyclical | Health |
52-Week High | $184.04 | $16.14 |
52-Week Low | $132.53 | $5.48 |
Enterprise Value | $47.28B | $607.68M |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $146.44, down slightly by 0.15% today, with a bullish technical signal from moving averages. The company reported Q3 2026 EPS of $3.20, beating estimates, but lowered full-year sales guidance due to soft demand. Valuation metrics appear reasonable with a P/E of 14.37 and P/S of 1.31, while profitability margins have compressed over recent years.
The outlook is mixed: strong cash flow and execution support the stock, but elevated mortgage rates and weak homebuying trends pose headwinds. Analyst consensus is a Buy with a $153 price target, indicating modest upside potential, though risks from housing market volatility persist.
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
